Everest Medicines' Zetomipzomib IND Accepted in China

-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis –  -...

December 04, 2023 | Monday | News
Perpetual Medicines Raises $8M in Seed Round for Peptide Drug Discovery Platform

Perpetual Medicines  announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for pe...

December 04, 2023 | Monday | News
Merck Expands Newest Biologics Testing Center in Shanghai

Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million Biologics Test...

November 29, 2023 | Wednesday | News
Surge in Respiratory Illness Overwhelms Chinese Hospitals, WHO Requests Data

A wave of respiratory illnesses, accompanied by alarming clusters of pneumonia cases, has inundated hospitals in northern China, sparking deep concerns abo...

November 25, 2023 | Saturday | News
Fapon Accelerates the Development of its Diagnostic Ecosystem

With a steadfast dedication of 22 years to advancing the fundamental technologies of raw materials, reagent and instrument, Fapon strives to empower the gl...

November 24, 2023 | Friday | News
STADA strikes partnership with CR Sanjiu in China to drive growth of its cough and cold portfolio

Partnership agreement signed on 22 November to broaden distribution and promotion of cough and cold brands such as Shidagong, Gelite and Ruike in China&n...

November 24, 2023 | Friday | News
Junshi Biosciences' VV116 COVID-19 Treatment Hits Lancet Infectious Diseases in Phase 3 Study Results

The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and ...

November 24, 2023 | Friday | News
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

"The NMPA approval of vebreltinib is an important milestone toward providing a new treatment option for patients with MET exon 14 skipping NSCLC in China. ...

November 17, 2023 | Friday | News
HUTCHMED announces FDA approval of FRUZAQLA™ for metastatic colorectal cancer in China, by Takeda.

U.S. approval of FRUZAQLA triggers first milestone payment from Takeda of US$35 million and royalties on net sales HUTCHMED (China) Limited (Nasdaq/AIM:HC...

November 09, 2023 | Thursday | News
Senti Bio Collaborates with Celest Therapeutics to Advance SENTI-301A in China

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...

November 07, 2023 | Tuesday | News
Merck Expands Oncology Portfolio with Hengrui Partnership, Promises More Treatment Options for Difficult-to-Treat Cancers

Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...

October 31, 2023 | Tuesday | News
LianBio Reports Phase 3 LIBRA Trial Results for TP-03 in Chinese Demodex Blepharitis

The co-primary endpoints of the LIBRA trial were mite eradication (mite density of 0 mites per lash) and complete collarette cure (collarette score of 0) a...

October 31, 2023 | Tuesday | News
Coherus and Junshi Biosciences Secure FDA Approval for LOQTORZI™ in All NPC Treatment Lines

Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing ...

October 30, 2023 | Monday | News
FDA Approves Etrasimod by Pfizer for Severe Ulcerative Colitis

Everest Medicines  announced  that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administratio...

October 16, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in